Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa is sold for research purposes primarily to major pharmaceutical companies for use in clinical studies. Following FDA approval expected in 2021, the large market for patient monitoring will be available.
We therefore invite you to a virtual Capital Markets Day on June 9, 2021 at 14.00 to 16.30.
Questions can be sent in advance or during the event to email@example.com
At the Capital Markets Day, among others, Luca Malorni, MD, PhD, will participate to give his view on DiviTum®TKa. Dr. Malorni is a medical oncologist and Director of the Translational Research Unit of the Hospital of Prato and principal investigator in several studies with DiviTum®TKa.